What is AscentGene?
AscentGene operates as a specialized biotechnology entity focused on the delivery of high-quality cell line and protein services. The company provides a comprehensive suite of solutions, including stable cell lines, recombinant proteins, and active cell extracts, which are essential for modern drug development and biomarker discovery. By serving a diverse clientele ranging from academic research institutions to large-scale pharmaceutical corporations, AscentGene has established itself as a vital link in the research and development value chain. Their technical expertise in protein expression, purification, and VLP production enables clients to streamline complex biological workflows, thereby reducing time-to-market for novel therapeutic candidates.
How much funding has AscentGene raised?
AscentGene has raised a total of $30K across 1 funding round:
Debt
$30K
Debt (2021): $30K with participation from PPP
Key Investors in AscentGene
PPP
Public-Private Partnership
What's next for AscentGene?
With the recent infusion of capital, AscentGene is poised to enter a new phase of strategic growth. The company is expected to prioritize the scaling of its laboratory infrastructure and the expansion of its proprietary protein expression platforms. As the firm transitions through its current Series B/C stage, management will likely focus on enhancing its service throughput and deepening its integration into the pharmaceutical R&D pipeline. This strategic roadmap aims to capitalize on the increasing demand for outsourced biological services, ensuring that AscentGene remains at the forefront of innovation in the life sciences sector while maintaining its commitment to rigorous quality standards.
See full AscentGene company page
